Rosana Kapeller, CEO of Rome Therapeutics, and Marty Taylor, physician-scientist at Harvard Medical School, join Vineeta Agarwala, general partner, and Bryan Faust, investment partner at a16z Bio + Health.
Together, they discuss Rosana and Marty's recent publication regarding a virus-like element in our genome known as LINE-1. LINE-1, part of our "dark genome," was ignored as junk DNA for years, but is increasingly recognized to contribute to the pathology of autoimmunity, cancer, neurodegeneration, and aging. Rosana and Marty discuss how the discovery was made as well as how Rome Therapeutics is developing a platform to target LINE-1 and other factors that are part of the "dark genome" for the treatment of disease.
Additional reading:
Journal Club: Restoring a Reflex
Sea Turtle Medicine
Journal Club: Assembling an Egg
The Art and Science of Biology's Future
Journal Club: Engineering Living Materials
Value Versus Volume (in Healthcare)
Things That Make You Go Hmmmm in Healthcare
Journal Club: My Tick Teacher
May I Have Your Insurance Card Again, Please?
Journal Club: Suppressing Superbugs
From Junk DNA to an RNA Revolution
Journal Club: Slaying the Sleeper Cells of Aging
The Fundamental Principles of Reality
Journal Club: A Safer Psychedelic
The Genetics of Risk
Journal Club: Synthetic Germs, Our Newest Weapon for Fighting Cancer
The Biology of Brain Organoids (or, Don't Call it a Brain in a Dish!)
Journal Club: Why do only some people get severe COVID-19?
So You Wanna Build a Software Company in Healthcare?
The Machine That Made the Vaccine
Create your
podcast in
minutes
It is Free